Population pharmacokinetics and pharmacodynamics of intraperitoneal aerosolized nanoparticle albumin‐bound paclitaxel (nab‐PTX) and metabolites
The developed model justifies a 140 mg/m<sup>2</sup> Phase 2 dose characterized by slow absorption and tolerable dose-related haematological and hepatic toxicity.
Authors
- Judith van Ovost (ORCID: https://orcid.org/0000-0002-2298-0404)
- Leen Van de Sande (ORCID: https://orcid.org/0000-0003-0006-8104)
- Louis Sandra (ORCID: https://orcid.org/0000-0002-7701-289X)
- P. De Sutter (ORCID: https://orcid.org/0000-0002-3064-3344)
- Martin Graversen (ORCID: https://orcid.org/0000-0001-5719-4916)
- A. Hoorens
- Sarah Cosyns (ORCID: https://orcid.org/0000-0002-5173-4296)
- Dr An Vermeulen
- W. Willaert
- Wim Ceelen
- Michael Bau Mortensen
Institutions
- Ghent University Hospital (BE)
- Odense University Hospital (DK)
- Ghent University (BE)
- Cancer Research Institute Ghent (BE)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1002/bcp.70529
- Primary Topic
- Protein Interaction Studies and Fluorescence Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00